Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.30 |
| ▸ | PAK4 | O96013 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16533302 | 0.86 | GABRA1 (0.33) | GABRA1GABRB1HTTKMT2AMET | |
| SCHEMBL30352415 | 0.84 | GABRA1 (0.36) | GABRA1GABRB1HTTKMT2AMET | |
| SCHEMBL23489745 | 0.84 | GABRA1 (0.36) | GABRA1GABRB1HTTKMT2AMET | |
| SCHEMBL30309363 | 0.84 | GABRA1 (0.36) | GABRA1GABRB1HTTKMT2AMET | |
| SCHEMBL13199698 | 0.84 | GABRA1 (0.36) | GABRA1GABRB1HTTKMT2AMET | |
| SCHEMBL26587450 | 0.81 | PDE2A (0.38) | GABRA1GABRB1HTTKMT2AMET | |
| SCHEMBL17143720 | 0.81 | HTT (0.35) | HTTKMT2ADYRK1A | |
| SCHEMBL16491238 | 0.78 | HRH4 (0.33) | RPS6KA3 | |
| SCHEMBL29009931 | 0.78 | PTGS2 (0.34) | GABRA1GABRB1KMT2A | |
| SCHEMBL26023822 | 0.78 | HTT (0.33) | HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11702407-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702407-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | GABRA1 1516/4885GABRB1 1692/4885HTT 4684/4885 |
| US-20230212149-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR3, LPAR1, LPAR2 | GABRA1 1083/4885GABRB1 1305/4885HTT 4781/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | GABRA1 1718/4885GABRB1 2239/4885HTT 4717/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | GABRA1 1718/4885GABRB1 2239/4885HTT 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.